Eisai to buy TorreyPines' Alzheimer's genetic research
This article was originally published in Scrip
Executive Summary
Eisaihas ended its collaborations with TorreyPines Therapeutics for basic research into the genetic mechanisms of Alzheimer's disease, and is to acquire all data and assets from the programmes. These looked at genes related to late-onset disease (which ended in September 2005) and whole-genome screening to elucidate pathogenesis (this September). Eisai will pay an undisclosed cash amount to the US firm, which is looking to progress several clinical-stage programmes. TorreyPines is also working on in-house gamma secretase modulators for Alzheimer's, for which it is seeking a development partner.
You may also be interested in...
Quotable: Words Of Wisdom From Our Recent APAC Coverage
Scrip's APAC team selects notable quotes from recent interviews, conferences and other coverage to highlight the views of senior executives and officials on the major topics facing the biopharma sector in the region.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: Teva’s immunology biosimilar launches; Intra-Cellular’s promising depression data; Phase III sleep apnea win for Lilly’s tirzepatide; an interview with Viking’s CEO; and China looks to define innovative drugs.
Quick Listen: Scrip's Five Must-Know Things
In this week's podcast edition of Five Must-Know Things: the shifting sands of pharma R&D; big pharma oncology strategies; semaglutide’s promise in heart failure; AstraZeneca looks to multiple cancer modalities; and an interview with Astellas’s chief strategy officer.